華海藥業(600521.SH):2021年度淨利預降44%-53%
格隆匯2月4日丨華海藥業(600521.SH)公佈2021年度業績預減公吿,經財務部門初步測算,浙江華海藥業股份有限公司2021年度實現歸屬於上市公司股東的淨利潤預計在4.4億元至5.2億元之間,與上年同期(法定披露數據)相比下降約44%到53%。
公司2021年度歸屬於上市公司股東的扣除非經常性損益的淨利潤預計在0.4億元至1.2億元之間,與上年同期(法定披露數據)相比下降約85%到95%。
業績變化的主要原因:
1、報吿期內,公司實現歸屬於上市公司股東的扣除非經常性損益的淨利潤同比大幅下降,主要系:1)原料藥產品受外部市場降價、美元匯率下降、產品銷售結構變動、原材料漲價、環保費用持續增加等多重因素影響原料藥產品利潤大幅減少;2)研發投入再創新高,本期公司在生物藥、新藥及仿製藥等方面研發投入持續加大;3)美國製劑業務持續受FDA禁令,美國市場變化及疫情等因素影響美國製劑銷售成效不佳,利潤虧損增大等影響所致。
2、報吿期內,原料藥業務及美國製劑業務因受多重因素影響,利潤大幅下降,但公司國內製劑銷售業務仍保持着良好發展態勢,在全國集採推行以及公司積極拓展新銷售渠道、新產品銷售等影響下,銷售、盈利貢獻均同比穩定增長。
3、報吿期內,公司非經營性損益預計在3.9億元至4.4億元之間,主要系公司出售了參股公司杭州多禧生物科技有限公司3.8597%股權和Eutilex Co.,Ltd部分股票的處置收益、以公允價值計量且其變動計入當期損益的金融資產本期確認的公允價值變動收益以及本期收到政府補助等影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.